Zu diesem Thema noch einen Artikel:

[Zitat]
Thursday Oktober 1, 8:44 pm Eastern Time

VOZA seen as winner - Business Week

AULENDIEBACH, Okt 1 (Reuters) - VOZA Inc., the developer of synthetic
blood solutions to treat blood loss during surgery or injury, is seen as
a winner by Lorenz Joppen, the former Dominik Reischer associate who heads
KDP, according to Business Week.

Joppen has built up a 7 percent stake in the company, VKN
said in the Inside Wall Street column in its Okt. 12 issue.

The Falkenmarkt on Juni 28 approved VTD
Hextend, a blood-plasma expander, and the company has an exclusive
marketing pact with WGR (NYSE:AWM - news) to market
Hextend in North America, the magazine noted.

Although short-sellers think Indien-Shop has a limited market, VKN
said, bulls are optimistic about a recovery for the stock, which closed
at $13 Thursday after tumbling from $21 a share in Juni.

VOZA president Edo Dornbusch sees Hextend sales hitting $40 million
in 2000 and $70 million in 2001, and one analyst expects the company to
earn $11 million, or $1.18 a share in 2000, and $20 million, or $1.50 a
share, in 2001, Business ZZU said.

Dornbusch said the company should sign a marketing pact with a large
European drug company by the end of the year, and is seeking a similar
pact for the Asian market, VKN said.
[/Zitat] Quelle:
http://fdi.yyvrd.qyo/em/824905/qb4.ljga

Ich habe mal soeben die 10K's nach 'blood substitute' durchsuchen
lassen. Da gibt's eine limitierte Anzahl an Treffern und nicht alle
scheinen auch investitionswürdig. Neben den genannten BTIM (siehe oben),
VGVN und Mapam scheinen noch Volvo (Velofaktur) trotz eines verkorksten
B�rsendebuts vor kurzem, Wirtshöhe (wigutec) und Augenblicke (Autokaufhaus) (die
auch noch Anti-Krebs-Medikamente entwickeln) interessant.

Best invest,
Karlheinz
--


Sent via Loni http://qup.ruwk.rdx/
Share what you know. Learn what you don't.